u/eu_apotheke_a

this is the recurring theme across every country thread: the cost-reduction mechanism exists, it is not advertised, and you find it on a forum.

On cross-border prescriptions, since the assumption behind half these threads is wrong.

There are EU rules on the recognition of prescriptions issued in another member state, and they are conditional: the prescription has to meet requirements about its form and content, certain categories are excluded, and pharmacies retain discretion in practice.

The result is that "my prescription will be accepted anywhere in the EU" is not a safe assumption, and members here have discovered it at a counter in another country. If it matters for a trip, check before you travel with the pharmacy and with somebody qualified where you are. Nothing on this board is advice about that, and the rules are national in their application whatever the framework says.

trial populations get support that nobody on this board gets

This is the distinction that would end about half the arguments on this board.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

Small fix — that was the cardiovascular outcomes trial, so weight was a secondary endpoint and the population was different.

The structure that makes this board make sense, once.

Marketing authorisation for these products is granted centrally, which is why the same product exists across the union. Everything after that — whether it is reimbursed, on what criteria, at what price, in what pack size, dispensed under what margin rules — is decided nationally.

So "is it covered" has twenty-seven answers, "what does it cost" has twenty-seven answers plus within-country variation, and only "is it authorised" has one. Almost every argument on this board is two people answering different questions from different countries, both correctly.

FLOW was kidney outcomes and it is the one nobody quotes

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

shortage status changes and the whole arrangement changes with it

the EMA authorises, member states decide who pays

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

Country added to the title — the answers differ across the union and the thread is unusable without it.

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

Did they name the facility?

Left up. It names the member state and the pack size, which is all we ask of a pricing post.

Is the prescription from the same country as the pharmacy?

Left up. It names the member state and the pack size, which is all we ask of a pricing post.

the shortage list is the whole legal hinge and people skip it

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

Same. Naming the country in the first line would fix most of the bad advice on this board.

The press release said that; the publication says something more hedged. Worth reading both.

do not assume the concentration matches the branded product

Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.

How to compare prices across borders without misleading yourself.

Normalise the pack size first. Presentations differ between member states and a headline figure for one pack is not comparable to another. Then separate reimbursed from private prices, which are set by entirely different mechanisms. Then note the dispensing fee structure, which is nationally regulated.

When members here have done all three, the interesting finding has consistently been that variation between pharmacies within a country is often as large as the variation between countries — which makes the cross-border shopping most of these threads are really about far less attractive than it looks.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences. Those are decided by different bodies with different processes.

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

Who is the prescriber, and are they the same organisation as the pharmacy?

Asked for potency testing on the finished preparation.

Disagreeing with this bit: registration is not equivalence, and the two get run together constantly.

the price difference is mostly the intake, not the vial

This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.

Left up. It names the member state and the pack size, which is all we ask of a pricing post.

a shortage in one member state is not a shortage in all of them

Country added to the title — the answers differ across the union and the thread is unusable without it.

A supply notice in one member state made the front page here and had no effect at all where I am.

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

the label on a compounded vial is a legal document, read it

Yes — keep both the prescription and the receipt. Claims processes ask for both and never at a convenient moment.